8SCHWARTZ G G,OLSSON A G,EZEKOWITZ M D,et al.Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes:the MIRACL study:a randomized controlled trial[J].JAMA,2001,285 (13):1711-1718. 被引量：1
9CHALASANI N,ALJADHEY H,KESTERSON J,et al.Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity[J].Gastroenterology,2004,126 (5):1287-1292. 被引量：1
10CANNON C P,BRAUNWALD E,MCLABE C H,et al.Pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 investigators.intensive versus moderate lipid lowering with statins after acute coronary syndromes[J].N Engl J Med,2004,350 (15):1495-1504. 被引量：1
4Meqa JL,Hochholzer W,Frelinger AL3rd,et al.Dosing clopidogrel based on CYP2C19genotype and the effect on platelet reactivity in patients with stable cardiovascular disease[J].JAMA,2011,306(20):2 221. 被引量：1
5Lindenmaier TJ,Buchanan DN,Pike D. One,two and three- dimensional ultrasound measurements of carotid atheroscle- rosis before and after cardiac rehabilitation:preliminary re- sults of a randomized controlled trial [J].Cardiovascular Ul- trasound,2013,22(11):39. 被引量：1
7Alaupovic P, Heinonen T, Shurzinske L, et al. Effect of a new HMG-CoA reductase inhibitor, atorvastatin, on lipids, apolip0proteins and lipoprotein particles in patients with ele- vated serum. Cholesterol and triglyceride levels[J].Atheroscle- rosis, 1997,133 (1)- 123-133. 被引量：1
